HLB's Rivoceranib Gains New Approval in China for Ovarian Cancer Treatment

· Rivoceranib in combination with Jiangsu Hengrui Pharma's fuzuloparib shows efficacy for ovarian cancer patients

HLB's rivoceranib gains new approval in China for ovarian cancer treatment (Image: HLB CI)

SEOUL, South Korea, April 22, 2024 (IT Times) - HLB, a leading biopharmaceutical company, today announced that the approval of its innovative anti-cancer drug rivoceranib in China for the treatment of ovarian cancer.

Rivoceranib is a VEGFR2 tyrosine kinase inhibitor, a targeted therapy that disrupts tumor growth and spread by blocking blood vessel formation and inhibiting cancer cell proliferation. Previously approved in China for treating advanced stages of gastric and liver cancer, rivoceranib now offers new hope for ovarian cancer patients who have undergone platinum-based chemotherapy.

Clinical trials have shown promising results for rivoceranib, particularly when combined with Jiangsu Hengrui Pharma's fuzuloparib, a small molecule, orally active PARP inhibitor. Fuzuloparib works by blocking a key enzyme involved in DNA repair in cancer cells, ultimately leading to cell death. The combination of these two drugs has the potential to significantly improve outcomes in ovarian cancer by simultaneously blocking both blood vessel formation and DNA repair mechanisms.

HLB's success extends beyond ovarian cancer. Rivoceranib has demonstrated exceptional results in combination therapies for liver cancer, with the PD- inhibitor camrelizumab. This versatility puts HLB, the global patent holder for rivoceranib, at the forefront of developing powerful and versatile cancer treatments.

Jiangsu Hengrui Pharma is actively conducting Phase III clinical trials to further explore rivoceranib's potential in treating various cancers, including adjuvant liver cancer, liver cancer with TACE (transarterial chemoembolization), breast cancer, gastric and esophageal cancer, and soon, prostate cancer.

"We aim to replicate the success of other blockbuster cancer drugs that have rapidly expanded their use to target multiple cancers," said Jang Jin-oo, Vice President of Investor Relations at HLB Group. "With ample resources following the recent approval in liver cancer, HLB is strategically positioned to unlock the full potential of rivoceranib. The drug's unique capabilities and extensive ongoing clinical trials in China, generating over a hundred investigator-driven data points annually, suggest that its scalability will surpass that of previous new drugs."

IT타임스 YoungHa Kim (yhkim@ittimes.com)

출처 IT타임스 : https://www.ittimes.com/news/articleView.html?idxno=30815

HLB's Rivoceranib Gains New Approval in China for Ovarian Cancer Treatment - IT타임스